Inside The COVID-19 Pipeline
An Interactive View Of Vaccines & Treatments In Development
Executive Summary
Updated daily as additional research gets underway, this pipeline tracker follows the global effort to find drugs that could help treat COVID-19 and the symptoms it causes, and accelerate a vaccine that could help limit the spread of the pandemic.
You may also be interested in...
Finance Watch: As Exit Values Rise, More Money Flows Into VC Investments
Private Company Edition: The average exit from biopharma investments rose from $356.8m in 2019 to $520.6m in 2020, explaining the staggering $12bn invested in the industry during the first half of this year versus $17bn for all of last year. In recent VC deals, VelosBio’s $137m series B was the largest.
Coronavirus Update: Can Deliberately Infecting Volunteers To Speed COVID-19 Vaccine Be Justified?
Plus: Sinovac promises to develop its vaccine for global use.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.